CureVac (CVAC) has released an update.
CureVac N.V., a trailblazer in mRNA technology, has appointed Dr. Mehdi Shahidi, an oncologist and veteran in drug development, to its Supervisory Board. Shahidi’s expertise is expected to advance CureVac’s focus on mRNA-based cancer vaccines and broaden its impact in oncology. His appointment underscores the company’s commitment to leveraging its mRNA platform to transform medicine, following significant contributions to COVID-19 vaccine development.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
